updated 2026 guidelines for treating blood lipids (and protecting your heart)

Heart Health in Midlife: Navigating the 2026 Lipid Guidelines

For women, midlife is a critical physiological “crossroad.” Beyond the familiar flushes and irritability, longterm risk of developing heart disease takes an up-kick at menopause. Heart disease remains the leading cause of death for women globally, yet it is frequently under-detected and its risk factors left untreated.

The 2026 American College of Cardiology (ACC) and the American Heart Association (AHA) guidelines represent a shift in recommendations. We are moving away from the binary “good vs. bad” cholesterol labels and toward a more precise understanding of unhealthy lipoprotein particles, cumulative lifetime risk, and the unique biological history of women.

Blood lipids – more than “good and bad” cholesterol

Lipoproteins and ApoB

Your blood is watery, but fats (cholesterol and triglycerides) are oily. To travel through your bloodstream, they must be packaged into “submarines” called lipoproteins.

This is a sophisticated recycling and delivery system:

• From Gut to Liver: After a meal, large particles (chylomicrons) carry fats from your gut to your liver.

• From Liver to Body: The liver repackages these into VLDL and LDL particles to deliver energy to your cells.

• Back to the Liver: Cleanup particles (HDL) pick up excess cholesterol to take back to the liver for disposal.

Every unhealthy particle that can cause plaque carries exactly one Apolipoprotein B (ApoB) molecule. Measuring ApoB gives a more accurate count of the total number of “submarines” with damage potential in your blood than just measuring the amount of cholesterol inside them. If your ApoB is high, your risk is high—even if your standard LDL-C looks “normal.”

Lipoprotein (a)

High Lp(a) is considered a key, often overlooked inherited cause of early cardiovascular disease, affecting roughly 20-25% of people. You only need to measure it once to know if you have this risk. Current drug treatments are not effective at lowering Lp(a) so control of all other risk factors eg lifestyle, stop smoking, lower APO B etc is vital.

Triglycerides and Insulin Resistance

Triglycerides are the most common type of fat in your body, used for energy. However, high levels are a major driver of atherosclerotic cardiovascular disease (ASCVD). High triglycerides are often a “red flag” for insulin resistance, frequently exacerbated by a diet high in refined carbohydrates and sugars. When insulin resistance is present, your liver produces more VLDL particles. These interact with other lipoproteins to create smaller, denser LDL particles that are more likely to get embedded in the artery wall, especially when inflammation (hsCRP) is present to “prime” the vessel lining.

Calculating your personal risk

The 2026 guidelines highlight the PREVENT-ASCVD Calculator. The US risk tool has been expanded to include people as young as 30, and to offer a 10 year and 30 year risk. This is valuable because young people will naturally have a low 5 year risk, clouding decisions to treat high lipids and missing the opportunity to prevent ASCVD longterm. An extended version included American zip codes, but adding these is optional. (The area you live in can give clues to socioeconomic disadvantage which is a risk factor for heart disease).

The Australian CVD Risk Calculator is based on the previous PREVENT equations and whilst including local postcodes, it only predicts a 5 year risk.

There is no harm in calculating both – don’t be confused if they differ, these are only estimates.

Note: If you already have Type 2 Diabetes, Chronic Kidney Disease, or existing heart disease, these calculators are not valid for you. You are already considered high-risk, and the guidelines recommend intensive treatment regardless of what a “score” says.

Risk Enhancers

A key pillar of the new guidelines is that a “low” or “intermediate” score on a risk calculator is not the final word. Risk enhancers are clinical factors that may justify starting Lipid-Lowering Therapy (LLT) even if your calculated risk seems low.

If you have any of the following, the benefit of starting treatment (like a statin) is likely much higher:

• Family History: A first-degree relative with premature heart disease (Men < 55y; Women < 65y).

• Primary Hypercholesterolaemia: LDL-C consistently greater than 4.1 mmol/L.

• Metabolic Syndrome: Increased waist circumference, high triglycerides (>1.7 mmol/L), low HDL, or high blood pressure.

• Chronic Kidney Disease: (eGFR 15–59 mL/min).

• Chronic Inflammatory Conditions: Psoriasis, Rheumatoid Arthritis, Lupus, or HIV.

• Female-Specific Factors: See below.

• High-Risk Biomarkers: Persistently elevated triglycerides (TG > 2.0 mmol/L), hsCRP > 2.0 mg/L, or a high Lp(a) level.

Female-Specific Risks

One of the most empowering aspects of the new guidelines is the formal recognition of female-specific “risk enhancers.” If you have experienced any of the following, your “true” heart risk is likely higher than a standard calculator suggests:

• Adverse Pregnancy Outcomes (APOs): A history of pre-eclampsia, gestational diabetes, or preterm birth is now recognised as a “failed stress test” for the heart. These conditions increase your risk of heart disease decades later.

• Premature Menopause: If you entered menopause before age 40, your heart has lost the protective effects of oestrogen much earlier than average, significantly increasing your cardiovascular risk.

• Inflammatory Conditions: Women are disproportionately affected by autoimmune diseases like Lupus or Rheumatoid Arthritis. These cause chronic inflammation (reflected in high hsCRP), which the guidelines now list as a major reason to consider starting statins earlier.

The Role of Coronary Artery Calcium Scores

If your risk remains uncertain, and the decision to use LLT is uncertain, a Coronary Artery Calcium (CAC) scan is recommended.

A CAC score of zero is excellent news, but it does not mean there is no plaque. It simply means there is no calcified (hardened) plaque. You could still have “soft” or “fatty” plaque that hasn’t hardened yet. This is why we still manage lifestyle and lipids even with a zero score—we want to prevent that soft plaque from ever forming or calcifying.

Lipid Lowering Therapy

There are various medications that can lower your lipids. These can be combined if necessary. Your risk and blood lipid levels determine what your target for LLKT should be. These targets are lower in the 2026 guidelines, reflecting the value in having lipids “lower for longer” to prevent the build up of plaque and the subsequent risk of heart disease, stroke, renal disease and peripheral vascular disease.

Most people can not typically “eat their way” to lower lipids. Much of the cholesterol in your body is made by your liver.

• Statins: First-line treatment. They lower liver cholesterol production and have various other impacts.

• Ezetimibe: Blocks cholesterol absorption in the gut.

• PCSK9 Inhibitors: Injectables that supercharge the liver’s ability to clear LDL particles.

• Bempedoic Acid: Lowers liver cholesterol production and inflammation.

On the basis that cholesterol is such an important compound in the brain, a common concern for women is whether lowering lipids affects cognitive function. The 2026 guidelines are firm: LLT does not cause dementia. In fact, by protecting the small blood vessels in the brain from plaque buildup, these treatments often help prevent vascular dementia and cognitive decline.

Targets (Australian Units)

• LDL-C: < 2.6 mmol/L (If you are intermediate risk) or < 1.8 mmol/L (if you are high risk).

• ApoB: < 80 mg/dL (or ~0.8 g/L).

• Inflammation: Check hsCRP; if > 2.0 mg/L, risk is enhanced.

• Triglycerides:  < 1.7 mmol/L; if high, discuss insulin resistance and diet.

Summary Checklist for your next GP Visit:

1. Calculate the PREVENT score: What is my 5/10/30-year heart risk?

2. Lp(a) Test: Have I had my “one-in-a-lifetime” genetic cholesterol check?

3. Reproductive History: Ensure your GP knows about any pregnancy complications or early menopause.

4. hsCRP: Check your inflammation levels.

5. CAC Scan: If there’s any doubt, “see” the plaque before deciding on treatment.

At Viv Health, we believe that midlife is not the beginning of the end, but the start of a “second act.” By following these new guidelines and advocating for your heart health today, you are ensuring that your second act is a long, healthy, and vibrant one.

Reference

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation March 2026